Novel Considerations in the Pathogenesis of the Antiphospholipid Syndrome: Involvement of the Tissue Factor Pathway of Blood Coagulation

 

 Buy Article Permissions and Reprints

ABSTRACT

The antiphospholipid syndrome (APS) is characterized by clinical manifestations such as venous and arterial thrombosis, thrombocytopenia and/or recurrent pregnancy loss, as well as the persistent presence of laboratory markers of antiphospholipid (aPL) antibodies detected in laboratory assays. Though it is generally accepted that aPL antibodies, such as anticardiolipin (aCL), anti–β2 glycoprotein I (anti-β2GPI), and lupus anticoagulants (LA) contribute to the pathogenesis of APS, precise mechanism(s) are yet to be fully described. It is probable that aPL antibodies bind to a range of cellular targets (e.g., platelets, endothelial cells, and monocytes), leading to thrombosis and obstetric complications. There is now increasing evidence that alterations to the tissue factor (TF) pathway of blood coagulation contribute toward hypercoagulability in patients with aPL antibodies. This article reviews current evidence that suggests changes and/or interference to the major pathway of blood coagulation may represent a novel mechanism that contributes to the development of APS.

REFERENCES

• 1 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
  CrossrefPubMedGoogle Scholar
• 2 Malia R G, Kitchen S, Greaves M et al.. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies.  Br J Haematol. 1990;  76 101-107
  CrossrefPubMedGoogle Scholar
• 3 Oosting J D, Derksen R H, Bobbink I W et al.. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?.  Blood. 1993;  81 2618-2625
  CrossrefPubMedGoogle Scholar
• 4 Amengual O, Atsumi T, Khamashta M A et al.. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.  Thromb Haemost. 1998;  79 276-281
  PubMedGoogle Scholar
• 5 Kornberg A, Blank M, Kaufman S et al.. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies.  J Immunol. 1994;  153 1328-1332
  PubMedGoogle Scholar
• 6 Escolar G, Font J, Reverter J C et al.. Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system.  Arterioscler Thromb. 1992;  12 196-200
  CrossrefPubMedGoogle Scholar
• 7 Pierangeli S S, Chen P P, Raschi E et al.. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.  Semin Thromb Hemost. 2008;  34 236-250
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Hoffman M, Monroe III D M. A cell-based model of hemostasis.  Thromb Haemost. 2001;  85 958-965
  PubMedGoogle Scholar
• 9 Mackman N, Tilley R E, Key N S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis.  Arterioscler Thromb Vasc Biol. 2007;  27 1687-1693
  CrossrefPubMedGoogle Scholar
• 10 Mallat Z, Benamer H, Hugel B et al.. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.  Circulation. 2000;  101 841-843
  CrossrefPubMedGoogle Scholar
• 11 Ederhy S, Di Angelantonio E, Mallat Z et al.. Levels of circulating procoagulant microparticles in nonvalvular atrial fibrillation.  Am J Cardiol. 2007;  100 989-994
  CrossrefPubMedGoogle Scholar
• 12 Tesselaar M E, Romijn F P, Van Der Linden I K et al.. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?.  J Thromb Haemost. 2007;  5 520-527
  CrossrefPubMedGoogle Scholar
• 13 Rauch U, Antoniak S. Tissue factor-positive microparticles in blood associated with coagulopathy in cancer.  Thromb Haemost. 2007;  97 9-10
  PubMedGoogle Scholar
• 14 Werling R W, Zacharski L R, Kisiel W et al.. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.  Thromb Haemost. 1993;  69 366-369
  Google Scholar
• 15 Adams M J, Oostryck R. A comparative study of functional assays for tissue factor pathway inhibitor using normal plasma and clinical samples.  Blood Coagul Fibrinolysis. 2000;  11 327-333
  CrossrefPubMedGoogle Scholar
• 16 Bognacki J, Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor.  Blood Coagul Fibrinolysis. 1995;  6(Suppl 1) S65-S72
  PubMedGoogle Scholar
• 17 Jeske W, Hoppensteadt D, Fareed J et al.. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations.  Blood Coagul Fibrinolysis. 1995;  6(Suppl 1) S73-S80
  CrossrefPubMedGoogle Scholar
• 18 Rustin M HA, Bull H A, Machin S J et al.. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus in endothelial cell prostacyclin release and procoagulant activity.  J Invest Dermatol. 1988;  90 744-748
  CrossrefPubMedGoogle Scholar
• 19 Hasselaar P, Derksen R H, Oosting J D et al.. Synergistic effect of low doses of tumour necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells.  Thromb Haemost. 1989;  62 654-660
  PubMedGoogle Scholar
• 20 Tannenbaum S H, Finko R, Cines D B. Antibody and immune complexes induce tissue factor production by human endothelial cells.  J Immunol. 1986;  137 1532-1537
  PubMedGoogle Scholar
• 21 Ferro D, Saliola M, Meroni P L et al.. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment.  J Thromb Haemost. 2003;  1 523-531
  CrossrefPubMedGoogle Scholar
• 22 Reverter J C, Tassies D, Font J et al.. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.  Arthritis Rheum. 1998;  41 1420-1427
  CrossrefPubMedGoogle Scholar
• 23 Jacobsen E M, Sandset P M, Wisloff F. Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?.  Thromb Res. 1999;  94 213-220
  CrossrefPubMedGoogle Scholar
• 24 Morel O, Jesel L, Freyssinet J M et al.. Elevated levels of procoagulant microparticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis.  Thromb J. 2005;  3 15
  CrossrefPubMedGoogle Scholar
• 25 Dignat-George F, Camoin-Jau L, Sabatier F et al.. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome.  Thromb Haemost. 2004;  91 667-673
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Enjeti A K, Lincz L F, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology.  Semin Thromb Hemost. 2007;  33 771-779
  Article in Thieme ConnectPubMedGoogle Scholar
• 27 Adams M, Breckler L, Stevens P et al.. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.  Haematologica. 2004;  89 985-990
  PubMedGoogle Scholar
• 28 Adams M J, Donohoe S, Mackie I J et al.. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome.  Br J Haematol. 2001;  114 375-379
  CrossrefPubMedGoogle Scholar
• 29 Adams M J, Dunstan R A, Oostryck R. Interference by lupus anticoagulant in a functional assay for tissue factor pathway inhibitor.  Thromb Res. 1995;  80 435-440
  CrossrefPubMedGoogle Scholar
• 30 Adams M J, Oostryck R. Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor.  Thromb Res. 1997;  87 245-249
  CrossrefPubMedGoogle Scholar
• 31 Lean S Y, Ellery P, Ivey L et al.. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.  Haematologica. 2006;  91 1360-1366
  PubMedGoogle Scholar
• 32 Forastiero R R, Martinuzzo M E, Broze G J. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome.  J Thromb Haemost. 2003;  1 718-724
  CrossrefPubMedGoogle Scholar
• 33 Salemink I, Blezer R, Willems G M et al.. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor.  Thromb Haemost. 2000;  84 653-656
  PubMedGoogle Scholar
• 34 Liestol S, Sandset P M, Jacobsen E M et al.. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.  Br J Haematol. 2007;  136 131-137
  CrossrefPubMedGoogle Scholar
• 35 Sheng Y, Hanly J G, Reddel S W et al.. Detection of ‘antiphospholipid’ antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin.  Clin Exp Immunol. 2001;  124 502-508
  CrossrefPubMedGoogle Scholar

Murray AdamsPh.D. M.A.I.M.S. 

School of Human Life Sciences, University of Tasmania

Tasmania, Australia

Email: Murray.Adams@utas.edu.au